← ANALYST RATINGS · TIPRANKS
Sana Biotechnology (SANA): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $9.50, the highest $12.00, the lowest $7.00. The average is +318.5% from the last price of $2.27.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $2.50+25.0% | Hold | +10.1% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $2.50+25.0% | Sell | +10.1% | Reiterated | 17.10.26on TipRanks Oct 16 22:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $3.00 → $2.50−16.7% | Hold | +10.1% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $3.00 → $2.50−16.7% | Hold | +10.1% | Reiterated | 08.10.26on TipRanks 05:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $3.50 → $2.50−28.6% | Hold | +10.1% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $3.50 → $2.50−28.6% | Hold | +10.1% | Reiterated | 07.10.26on TipRanks 02:05 | — | |
| Emily Bodnar★★★★★★★★★★#2140 · hits 39% · avg +7.2% | H.C. Wainwright | $7.00 | Buy | +208.4% | Reiterated | 21.09.26on TipRanks 13:55 | −1.6%next day +7.4% · 5 days −4.5% | ↗ |
| Maxwell Skor★★★★★★★★★★#486 · hits 74% · avg +28.0% | Morgan Stanley | $12.00 | Buy | +428.6% | Assigned | 17.08.26on TipRanks 08:55 | +4.1%next day −0.7% · 5 days +3.9% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $7.00 → $6.00−14.3% | Buy | +164.3% | Reiterated | 14.08.26on TipRanks 07:10 | −3.1%next day +4.1% · 5 days +11.5% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 11.08.26on TipRanks Aug 12 02:25 | +5.3%next day −0.8% · 5 days −3.8% | ↗ |
| Martin Fan★★★★★★★★★★#177 · hits 87% · avg +94.8% | Wedbush | $7.00 | Buy | +208.4% | Reiterated | 11.08.26on TipRanks 08:12 | +5.3%next day −0.8% · 5 days −3.8% | ↗ |
| Michael King★★★★★★★★★★#11053 · hits 39% · avg −2.3% | Rodman & Renshaw | $16.00 | Buy | +604.8% | Initiated | 11.05.26on TipRanks 08:05 | +1.2%next day −8.3% · 5 days −14.5% | ↗ |
| Samantha Semenkow★★★★★★★★★★#6889 · hits 47% · avg +0.7% | Citi | $12.00 | Buy | +428.6% | Reiterated | 04.03.26on TipRanks Mar 5 05:35 | −3.5%next day −10.2% · 5 days −16.3% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $5.00 → $8.00+60.0% | Buy | +252.4% | Reiterated | 30.10.25on TipRanks 07:15 | −7.7%next day +0.7% · 5 days −15.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Sana Biotechnology
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $8.00 at a price of $2.92 (+174.4%); now: $8.00 at $2.27 (+252.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 2 | 2 | 2 | 2 |
| Buy | 3 | 2 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.15 (from $-0.21 to $-0.12). Last quarter: $-0.22.
Best top-analyst consensus in the sector · Healthcare
About Sana Biotechnology
- CEO: Steven D. Harr
- Employees: 142
- 188 East Blaine Street, Seattle, WA, 98102, US
- www.sana.com
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses. Its portfolio of drug candidates includes SG295 and SG242, which are designed to target CD19+ cancer cells involved in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. For multiple myeloma, Sana is progressing SG221, SG239, and SC255. Other pipeline assets include SG328 for ornithine transcarbamylase deficiency, and SG418 for sickle cell disease and beta-thalassemia. Additionally, the company is advancing SC291, a CD19 allogeneic T cell therapy, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Founded in 2018 as FD Therapeutics, Inc., the company adopted its current name, Sana Biotechnology, Inc., in September 2018 and is based in Seattle, Washington.
Data from the stock’s TipRanks forecast page, read 178 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗